Collectively, preclinical studies of CD47 blockade have demonstrated encouraging activity associated with enhanced phagocytic clearance of cancer cells and induction of anti-tumor immunity, stimulating the development of numerous agents for CD47-targeted therapy. Here, CD47 is linked to cancer.